COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Jazz Pharmaceuticals

Both of these biotech stocks are innovators, but one is more likely to hit it out of the park.

Better Buy: Compass Pathways vs. Jazz Pharmaceuticals

Hours after psychedelic leader Compass Pathways (NASDAQ:CMPS) announced Phase IIb results from the largest modern study on a psychedelic substance, the stocks of most psychedelic companies holistically took a nosedive despite generally positive results.  Peter Theil-backed Compass published data revealing that a strong dose of its  Comp360 medication (a psiloCybin (NEO:CYBN)-derivative in a crystalline form) helped reduce depression in patients suffering from the treatment-resistant mental health issue.

Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental health

Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.

Is Now the Right Time to Buy Compass Pathways?

Positive trial results weren't enough to keep the company's shares from sinking this week.

Why Compass Pathways Stock Slumped This Week

Mind Medicine MindMed

Atai Life Sciences BV

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential

Investors might want to give this psychedelic stock another look.

Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?

The stock dropped more than $13 on Tuesday.

Why Compass Pathways Shares Are Slumping More Than 22% Tuesday

​​​​​Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with rapid and durable treatment response.

Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial

LONDON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2021 and gave an update on recent progress across its business.

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder (PTSD). The study expands COMPASS's research pipeline in psilocybin therapy with COMP360, the company's proprietary formulation of synthetic psilocybin which COMPASS is currently developing for treatment-resistant depression.

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

Their clinical programs and research-enabling technologies both surpass the competition.

These 4 Psychedelic Biotech Stocks Are Leading the Pack

It depends on how optimistic you are about its lead program.

Down 25% in 2021, Is Compass Pathways Undervalued?

Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedelics space, has been granted its fourth patent by the US Patent and Trademark Office. The company's flagship phase 2 research program on psilocybin for depression marks the industry's most advanced pipeline on a “classic psychedelic” molecule; including LSD, mescaline, DMT or psilocybin itself, also known as the active compound in so-called “magic mushrooms.

Psychedelic Unicorn Compass Pathways Receives New Patent Approval

Investigator-initiated study shows remission in major depression symptoms for 50% of participants

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). This is COMPASS's first patent with claims covering its Form A hydrate psilocybin. The Form A hydrate is distinct from the anhydrate psilocybin for which the company has already been granted eight patents in the US, UK, Germany and Hong Kong, and which is used in COMP360, COMPASS's synthesised psilocybin formulation being developed for psilocybin therapy in treatment-resistant depression.

COMPASS Pathways is granted new US patent for crystalline psilocybin

Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.

Why Compass Pathways Stock Dropped 12% in September

Ionis Pharma

Neurocrine Biosciences

Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.

3 Biotech Stocks With Huge Catalysts This Fall

Here's a pharmaceutical company that could have an incredibly bright future.

1 Recent Healthcare IPO to Put on Your Radar

London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming investor conferences as follows:

COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences

Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances. Compass reached unicorn status after becoming the first company in the sector to IPO on the Nasdaq last year.

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances. The IP was developed together with inventor Matthias Grill PhD, founder and CEO of MiHKAL GmbH in Basel, Switzerland, who will be working with COMPASS on an exclusive research project to develop new product candidates.

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a full-time consultant, who will be working primarily at the COMPASS Discovery Center, based at University of the Sciences in Philadelphia (USciences) in the United States. Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Ameri Holdings

Field Trip Health Ltd

The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.

News for COMPASS Pathways Stock (CMPS)